This drug led to 50% more weight loss than Wegovy in head-to-head study

Deciding which jab to nab?When it comes to shedding pounds and cinching inches, a new study puts one weight loss drug ahead of another.Published in the New England Journal of Medicine, the study followed 751 obese Americans to test the efficacy and safety of two leading weight loss drugs.Participants, none of whom are diabetic, were given weekly injections of either Zepbound, Eli Lilly’s obesity drug, or Novo Nordisk’s Wegovy.Both medications contribute to weight loss by mimicking appetite-regulating hormones.

Zepbound targets two hormones, GLP-1 and GIP, while Wegovy targets only GLP-1.A staggering 1 in 8 adults in the US have used a GLP-1.After 72 weeks, participants receiving the Zepbound injections lost an average of 50 pounds, or 20% of their body weight.In contrast, Weogovy users lost an average of 33 pounds or 14% of their body weight.In terms of waist size, Zepbound users lost an average of 7 inches, compared to 5 inches with Wegovy.

Nearly 32% of Zepbound users ultimately lost at least a quarter of their body weight, compared with just 16% of Wegovy users.In both groups, weight loss was about 6% lower in men than in women.These findings were presented at the European Congress on Obesity in Malaga, Spain.Roughly 75% of participants in both groups reported mild to moderate stomach issues.

A recent report found that more than 30% of GLP-1 patients drop the meds after just four weeks because they suffer early side effects like nausea or other digestive problems.In the latest study, 6% of Zepbound users and 8% of Wegovy users left the trial due to side effects.These medications slow down the passage of food through the stomach, allowing people to feel fuller, longer. However, issues arise if the drugs slow down the stomach too much and, in some cases, can lead to severe gastroparesis, or stomach paralysis.The Post previously reported that about 30% of Wegovy users have experienced diarrhea, including some who claim they’ve woken up in the midd...